Skip to content
Biodatica
Start free

Guangdong Association of Clinical Trials

Guangzhou, Guangdong

OncologyPhase II
Compare Sign in to watch

What changed

Study registered, no phase assigned: Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

1w agoTrial registeredJul 10, 2026Source filing (opens the source filing in a new tab)

Momentum

96no change

Momentum 96 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,438 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jan 20, 2026

    Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease, PD-L1 Positive, as Determined by a Validated Assay · RECRUITING · sponsor: Guangdong Association of Clinical Trials · Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

    ClinicalTrials.gov · NCT07696832 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Jan 1, 2026

    Dry Eye, Cataract · RECRUITING · sponsor: Jin Yang · Effect of Dry Eye Treatment on Corneal Astigmatism Measurements

    ClinicalTrials.gov · NCT07657858 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Jan 1, 2025

    Fuchs Endothelial Corneal Dystrophy, Cataract · RECRUITING · sponsor: Eye & ENT Hospital of Fudan University · Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts

    ClinicalTrials.gov · NCT06966167 (opens the source filing in a new tab)

  4. Trial

    NA registered

    Jan 1, 2025

    Cataract · RECRUITING · sponsor: Jin Yang · Postoperative Rotational Dynamics of Three Toric Intraocular Lens Designs

    ClinicalTrials.gov · NCT07453992 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Jul 7, 2023

    Small-cell Lung Cancer · RECRUITING · sponsor: Guangdong Association of Clinical Trials · Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

    ClinicalTrials.gov · NCT05957510 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources